A PHASE I TRIAL OF SUBCUTANEOUS, OUTPATIENT INTERLEUKIN-2 FOR PATIENTS WITH MYELODYSPLASTIC SYNDROME (MDS).
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Aldesleukin (Primary)
- Indications Myelodysplastic syndromes
- Focus Adverse reactions
- 27 Feb 2019 Biomarkers information updated
- 25 Sep 2005 New trial record.